US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist
  • 0.800
  • -0.028-3.32%
Trading Nov 7 14:25 ET
204.60MMarket Cap-2222P/E (TTM)

Adaptimmune Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
Total revenue
2,399.63%128.23M
-88.07%5.68M
122.05%60.28M
-97.91%231K
4.45%7.32M
-7.37%5.13M
1,231.50%47.6M
341.50%27.15M
678.26%11.03M
482.46%7.01M
Operating revenue
2,399.63%128.23M
-88.07%5.68M
122.05%60.28M
-97.91%231K
4.45%7.32M
-7.37%5.13M
1,231.50%47.6M
341.50%27.15M
678.26%11.03M
482.46%7.01M
Cost of revenue
Gross profit
Operating expense
18.97%59.53M
24.18%54.94M
5.03%198.32M
39.23%50.09M
7.91%53.95M
1.52%50.04M
-17.39%44.24M
12.13%188.82M
-18.76%35.97M
15.24%50M
Selling and administrative expenses
-4.93%19.08M
5.55%19.73M
17.55%71.81M
30.63%16.88M
-3.87%16.16M
37.96%20.07M
11.25%18.69M
6.61%61.09M
-12.55%12.92M
10.82%16.82M
-General and administrative expense
-4.93%19.08M
5.55%19.73M
17.55%71.81M
30.63%16.88M
-3.87%16.16M
37.96%20.07M
11.25%18.69M
6.61%61.09M
-12.55%12.92M
10.82%16.82M
Research and development costs
34.98%40.45M
37.81%35.21M
-0.95%126.51M
44.06%33.21M
13.88%37.79M
-13.74%29.97M
-30.49%25.55M
14.98%127.73M
-21.87%23.05M
17.62%33.18M
Operating profit
252.98%68.7M
-1,566.54%-49.26M
14.62%-138.04M
-99.86%-49.86M
-8.47%-46.63M
-2.64%-44.91M
106.72%3.36M
0.36%-161.67M
41.80%-24.95M
-1.92%-42.99M
Net non-operating interest income expense
-44.91%850K
98.96%1.35M
286.77%5.96M
205.16%1.6M
563.27%2.15M
332.21%1.54M
100.00%676K
40.82%1.54M
192.18%523K
44.00%324K
Non-operating interest income
-10.82%1.38M
98.96%1.35M
286.77%5.96M
205.16%1.6M
563.27%2.15M
332.21%1.54M
100.00%676K
40.82%1.54M
192.18%523K
44.00%324K
Non-operating interest expense
--526K
----
----
----
----
--0
----
----
----
----
Other net income (expense)
-97.81%497K
97.43%-61K
789.69%19.54M
91.84%-313K
-126.16%-430K
3,558.93%22.66M
-19,883.33%-2.37M
-173.55%-2.83M
-195.00%-3.83M
793.67%1.64M
Special income (charges)
--0
--0
985.76%20.35M
--0
---106K
--22.16M
---1.7M
---2.3M
---2.3M
--0
-Less：Restructuring and merger&acquisition
--0
--0
-985.76%-20.35M
--0
--106K
---22.16M
--1.7M
--2.3M
--2.3M
--0
Other non- operating income (expenses)
-0.80%497K
90.91%-61K
-50.56%-807K
79.64%-313K
-119.71%-324K
176.49%501K
-5,691.67%-671K
-113.91%-536K
-138.08%-1.54M
793.67%1.64M
Income before tax
438.24%70.05M
-2,988.44%-47.98M
30.94%-112.54M
-71.90%-48.57M
-9.49%-44.91M
52.99%-20.71M
103.35%1.66M
-3.60%-162.96M
26.89%-28.26M
2.78%-41.02M
Income tax
-22.65%526K
-15.84%526K
-46.50%1.34M
-166.00%-656K
72.18%687K
44.68%680K
-1.42%625K
215.68%2.5M
375.60%994K
91.83%399K
Net income
425.03%69.52M
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
2.31%-41.42M
Net income continuous Operations
425.03%69.52M
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
2.31%-41.42M
Minority interest income
Net income attributable to the parent company
425.03%69.52M
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
2.31%-41.42M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
425.03%69.52M
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
2.31%-41.42M
Basic earnings per share
350.00%0.3
-2,970.81%-0.18
47.06%-0.54
0.00%-0.18
25.00%-0.18
60.00%-0.12
102.09%0.0063
0.00%-1.02
25.00%-0.18
20.00%-0.24
Diluted earnings per share
300.00%0.24
-2,996.68%-0.18
47.06%-0.54
0.00%-0.18
25.00%-0.18
60.00%-0.12
102.07%0.0062
0.00%-1.02
25.00%-0.18
20.00%-0.24
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022
Total revenue 2,399.63%128.23M-88.07%5.68M122.05%60.28M-97.91%231K4.45%7.32M-7.37%5.13M1,231.50%47.6M341.50%27.15M678.26%11.03M482.46%7.01M
Operating revenue 2,399.63%128.23M-88.07%5.68M122.05%60.28M-97.91%231K4.45%7.32M-7.37%5.13M1,231.50%47.6M341.50%27.15M678.26%11.03M482.46%7.01M
Cost of revenue
Gross profit
Operating expense 18.97%59.53M24.18%54.94M5.03%198.32M39.23%50.09M7.91%53.95M1.52%50.04M-17.39%44.24M12.13%188.82M-18.76%35.97M15.24%50M
Selling and administrative expenses -4.93%19.08M5.55%19.73M17.55%71.81M30.63%16.88M-3.87%16.16M37.96%20.07M11.25%18.69M6.61%61.09M-12.55%12.92M10.82%16.82M
-General and administrative expense -4.93%19.08M5.55%19.73M17.55%71.81M30.63%16.88M-3.87%16.16M37.96%20.07M11.25%18.69M6.61%61.09M-12.55%12.92M10.82%16.82M
Research and development costs 34.98%40.45M37.81%35.21M-0.95%126.51M44.06%33.21M13.88%37.79M-13.74%29.97M-30.49%25.55M14.98%127.73M-21.87%23.05M17.62%33.18M
Operating profit 252.98%68.7M-1,566.54%-49.26M14.62%-138.04M-99.86%-49.86M-8.47%-46.63M-2.64%-44.91M106.72%3.36M0.36%-161.67M41.80%-24.95M-1.92%-42.99M
Net non-operating interest income expense -44.91%850K98.96%1.35M286.77%5.96M205.16%1.6M563.27%2.15M332.21%1.54M100.00%676K40.82%1.54M192.18%523K44.00%324K
Non-operating interest income -10.82%1.38M98.96%1.35M286.77%5.96M205.16%1.6M563.27%2.15M332.21%1.54M100.00%676K40.82%1.54M192.18%523K44.00%324K
Non-operating interest expense --526K------------------0----------------
Other net income (expense) -97.81%497K97.43%-61K789.69%19.54M91.84%-313K-126.16%-430K3,558.93%22.66M-19,883.33%-2.37M-173.55%-2.83M-195.00%-3.83M793.67%1.64M
Special income (charges) --0--0985.76%20.35M--0---106K--22.16M---1.7M---2.3M---2.3M--0
-Less：Restructuring and merger&acquisition --0--0-985.76%-20.35M--0--106K---22.16M--1.7M--2.3M--2.3M--0
Other non- operating income (expenses) -0.80%497K90.91%-61K-50.56%-807K79.64%-313K-119.71%-324K176.49%501K-5,691.67%-671K-113.91%-536K-138.08%-1.54M793.67%1.64M
Income before tax 438.24%70.05M-2,988.44%-47.98M30.94%-112.54M-71.90%-48.57M-9.49%-44.91M52.99%-20.71M103.35%1.66M-3.60%-162.96M26.89%-28.26M2.78%-41.02M
Income tax -22.65%526K-15.84%526K-46.50%1.34M-166.00%-656K72.18%687K44.68%680K-1.42%625K215.68%2.5M375.60%994K91.83%399K
Net income 425.03%69.52M-4,781.76%-48.5M31.18%-113.87M-63.82%-47.92M-10.09%-45.6M51.96%-21.39M102.06%1.04M-4.66%-165.46M24.73%-29.25M2.31%-41.42M
Net income continuous Operations 425.03%69.52M-4,781.76%-48.5M31.18%-113.87M-63.82%-47.92M-10.09%-45.6M51.96%-21.39M102.06%1.04M-4.66%-165.46M24.73%-29.25M2.31%-41.42M
Minority interest income
Net income attributable to the parent company 425.03%69.52M-4,781.76%-48.5M31.18%-113.87M-63.82%-47.92M-10.09%-45.6M51.96%-21.39M102.06%1.04M-4.66%-165.46M24.73%-29.25M2.31%-41.42M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 425.03%69.52M-4,781.76%-48.5M31.18%-113.87M-63.82%-47.92M-10.09%-45.6M51.96%-21.39M102.06%1.04M-4.66%-165.46M24.73%-29.25M2.31%-41.42M
Basic earnings per share 350.00%0.3-2,970.81%-0.1847.06%-0.540.00%-0.1825.00%-0.1860.00%-0.12102.09%0.00630.00%-1.0225.00%-0.1820.00%-0.24
Diluted earnings per share 300.00%0.24-2,996.68%-0.1847.06%-0.540.00%-0.1825.00%-0.1860.00%-0.12102.07%0.00620.00%-1.0225.00%-0.1820.00%-0.24
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----Unqualified Opinion--------Unqualified Opinion----

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Concept CAR-T Therapy
CAR-T Therapy
Intraday+0.48%